• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MiMedx files SEC shelf registration to sell up to $350M in securities

August 27, 2021 By Sean Whooley

MiMedxMiMedx (NSDQ:MDXG) announced today that it filed a shelf registration statement on Form S-3 with the SEC.

Marietta, Ga.-based MiMedx, which develops AmnioFix, a micronized dehydrated human amnion/chorion membrane (dHACM) injection as regenerative medicine, will be allowed to sell up to $350 million in various types of securities over the next three years once the SEC declares the shelf registration effective.

“MiMedx has come a long way in restoring its financial stability, reporting integrity, and overall reputation as a Nasdaq-listed company throughout the past 12 months, and I am pleased that we have met the conditions for S-3 eligibility,” MiMedx CFO Peter M. Carlson said in a news release. “While there are no specific plans to issue securities under the registration statement at this time, this filing is a matter of good corporate governance and will provide the company with flexibility to finance future growth initiatives by accessing the capital markets on a timely and cost-effective basis.”

The financial stability referenced by Carlson goes back to recent struggles following the sentencing of the company’s former CEO Parker Petit and COO William Taylor to one year in prison for their involvement in a scheme to fraudulently inflate the company’s reported revenue in 2015 and 2016.

In May, a federal judge ruled that MiMedx cannot recoup $40.2 million from the two former executives convicted in the scheme to defraud the company and its investors. The company did recently post Street-beating second-quarter financial results, showcasing what Carlson points to as the road to restoring financial stability.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Regenerative Medicine Tagged With: mimedx, Securities and Exchange Commission (SEC)

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS